title: Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors?
abstract: Conversion to mammalian target of rapamycin inhibitors (mTORi) is an ever more frequent practice in renal transplant recipients, even if it is not always satisfactory, needing to be suspended for various reasons in certain patients. We analyzed the evolution of proteinuria as a marker of kidney damage after withdrawal of mTORi for any reason in order to assess conversion failure risk. Among 1633 renal transplant patients with 185 converted to mTORi, we considered the 52 (28%) who withdrew as result of intolerance or a bad evolution after at least 3 months use (median: 142 days after conversion). Four groups were defined according to the evolution of proteinuria: group 1 (G1), stable after conversion; group 2 (G2), increased with complete recovery (<1 g); group 3 (G3), increased with partial recovery (>1 g); or group 4 (G4), increased without recovery. The evolution according to the groups was: G1 (57.1%), G2 (17.2%), G3 (5.7%), and G4 (20%). There were no differences between the good (G1 and G2) and the bad evolution groups (G3 and G4) in proteinuria at the time of conversion (838 ± 641 vs 532 ± 404 mg/d) or renal function (1.95 ± 0.47 vs 1.90 ± 0.4 mg/dL). Six months after withdrawal, proteinuria was stable in G1 and G2 but worse in G3 and G4 (781 ± 643 vs 4479 ± 3235 mg/d); the same observation was noted for renal failure (2.1 ± 0.71 vs 2.8 ± 1.57 mg/dL). Among about 75% of patients in whom mTORi was withdrawn, no injury remained in the medium term whereas among the other 25%, there was a residual injury.
authors.affiliation: Department of Nephrology, Universitary Hospital Marques de Valdecilla-IFIMAV, Santander, Spain. alvaroarnau@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Arnau
authors.forename: J C
authors.initials: JC
authors.lastname: Ruiz
authors.forename: E
authors.initials: E
authors.lastname: Rodrigo
authors.forename: J A
authors.initials: JA
authors.lastname: Quintanar
authors.forename: M
authors.initials: M
authors.lastname: Arias
mesh_terms: D015415:Biomarkers / Q000097:blood; D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D057915:Drug Substitution; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology; D011507:Proteinuria / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D012189:Retrospective Studies; D013030:Spain; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D013997:Time Factors
chemical_list: D015415:Biomarkers; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D003404:Creatinine; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases